

Supplemental Table 1: ARIA-H<10mm incidence rates per 100 person-years by baseline demographics, medical history and MR images.

		Subjects at risk	Subjects with new onset ARIA- H<10mm	Person- Years	Rate per 100 person-years	95% Confidence Interval	
						Lower Limit	Upper Limit
Overall		301	30	410.59	7.31	5.03	10.29
Arm							
	Placebo	100	3	117.71	2.55	0.71	6.80
	Bapineuzumab	201	27	292.89	9.22	6.21	13.21
Dose							
	0.0 mg/kg	100	3	117.71	2.55	0.71	6.80
	0.15mg/kg	42	5	74.81	6.68	2.53	14.65
	0.5 mg/kg	57	9	74.37	12.10	5.98	22.09
	1.0 mg/kg	62	6	90.77	6.61	2.75	13.62
	2.0 mg/kg	40	7	52.93	13.23	5.90	25.97
APOE ε4 allele frequency							
	None	101	3	155.63	1.93	0.53	5.14
	One (heterozygote)	149	14	196.15	7.14	4.09	11.66
	Two (homozygote)	51	13	58.82	22.10	12.38	36.72
ARIA-H <10mm (small ARIA-H) at baseline							
	None	273	21	378.07	5.5		
	Yes	28	9	32.52	27.6		
ARIA-H <10mm, number at baseline							

Legend: "Months relative to start of active therapy"

		95% Confidence Interval					
		Subjects at risk	Subjects with new onset ARIA- H<10mm	Person- Years	Rate per 100 person-years	Lower Limit	Upper Limit
	0	273	21	378.07	5.55	3.54	8.33
	1	21	5	27.28	18.33	6.95	40.18
	2	1	0	2.87	0.00		85.87
	4	1	0	0.11	0.00		2195.01
	5	1	1	0.55	181.72	16.48	847.18
	7	2	1	1.48	67.64	6.13	315.34
	20	1	1	0.12	849.42	77.04	3960.05
	25	1	1	0.12	849.42	77.04	3960.05
ARIA-H <10mm	2 or more	7	4	5.25	76.25	25.49	181.29
ARIA-H ≥10mm (large ARIA-H) at baseline							
	None	296	29	404.67	7.17	4.90	10.15
	Yes	5	1	5.93	16.87	1.53	78.65
White Matter Hyperintensities (at baseline)							
	None or Focal	264	25	365.68	6.84	4.53	9.93
	Beginning of Confluent or Diffuse	37	5	44.91	11.13	4.22	24.40
ARIA- E							
	No	299	29	405.94	7.14	4.88	10.11
	Yes	2	1	4.65	21.50	1.95	100.22
Modified Hachinski Score							

		95% Confidence Interval					
		Subjects at risk	Subjects with new onset ARIA- H<10mm	Person- Years	Rate per 100 person-years	Lower Limit	Upper Limit
	<= 0.5	162	13	227.35	5.72	3.20	9.50
	>0.5	139	17	183.24	9.28	5.61	14.52
Antithrombotic use							
	No	159	10	220.87	4.53	2.32	8.03
	Yes	142	20	189.73	10.54	6.64	15.96
Hypertension*							
	No	214	21	291.67	7.20	4.59	10.80
	Yes	87	9	118.93	7.57	3.74	13.81
Age in years							
	< 72 years	168	14	234.86	5.96	3.41	9.73
	72 or more years	133	16	175.73	9.10	5.42	14.43
Gender							
	Men	140	17	197.47	8.61	5.21	13.47
	Women	161	13	213.12	6.10	3.42	10.13
Hamilton Psychiatric Rating Scale for Depression Score							
	<=2.0	193	22	271.84	8.09	5.22	12.03
	>2.0	107	7	138.39	5.06	2.26	9.93

Hypertension is defined by either the use of an antihypertensive therapy, systolic blood pressure greater than 140mm Hg or diastolic blood pressure greater than 90mm Hg.

Supplemental Table 2 Incidence rates per 100 person-years for ARIA-H<10mm by baseline demographics, medical history and MR images. (additional information from table 2)

		Subjects at risk, n	Subjects with incident ARIA- H<10mm, n	Person- Years	Rate per 100 person-years	95% Confidence Interval	
						Lower Limit	Upper Limit
Dose mg/kg							
ARIA-H <10mm present at baseline							
0	No	92	1	110.35	0.91	0.08	4.22
0	Yes	8	2	7.35	27.21	5.43	87.21
0.15	No	38	3	68.28	4.39	1.22	11.72
0.15	Yes	4	2	6.53	30.62	6.11	98.14
0.5	No	50	8	64.56	12.39	5.85	23.38
0.5	Yes	7	1	9.82	10.19	0.92	47.49
1	No	56	4	84.42	4.74	1.58	11.26
1	Yes	6	2	6.35	31.49	6.28	100.93
2	No	37	5	50.46	9.91	3.76	21.72
2	Yes	3	2	2.47	80.99	16.15	259.60
Dose mg/kg							
Modified Hachinski Score							
0	<=0.5	54	1	66.84	1.50	0.14	6.97
0	>0.5	46	2	50.86	3.93	0.78	12.60
0.15	<=0.5	23	1	40.06	2.50	0.23	11.64
0.15	>0.5	19	4	34.75	11.51	3.85	27.37
0.5	<=0.5	29	5	38.58	12.96	4.92	28.41

		95% Confidence Interval						
		Subjects at risk, n	Subjects with incident ARIA- H<10mm, n	Person- Years	Rate per 100 person-years	Lower Limit	Upper Limit	
0.5	>0.5	28	4	35.79	11.18	3.74	26.57	
1	<=0.5	33	2	52.38	3.82	0.76	12.24	
1	>0.5	29	4	38.40	10.42	3.48	24.77	
2	<=0.5	23	4	29.49	13.56	4.53	32.25	
2	>0.5	17	3	23.44	12.80	3.54	34.15	
Dose mg/kg		Antithrombotic use						
0	No	60	1	70.80	1.41	0.13	6.58	
0	Yes	40	2	46.90	4.26	0.85	13.67	
0.15	No	22	2	40.65	4.92	0.98	15.77	
0.15	Yes	20	3	34.16	8.78	2.43	23.43	
0.5	No	24	3	32.48	9.24	2.56	24.64	
0.5	Yes	33	6	41.89	14.32	5.95	29.52	
1	No	29	0	45.44	0.00		5.42	
1	Yes	33	6	45.34	13.23	5.50	27.28	
2	No	24	4	31.50	12.70	4.25	30.19	
2	Yes	16	3	21.43	14.00	3.87	37.34	
Dose mg/kg		Elevated Blood Pressure at Baseline						
0	No	69	3	80.75	3.72	1.03	9.91	
0	Yes	31	0	36.96	0.00		6.67	
0.15	No	25	1	44.39	2.25	0.20	10.50	
0.15	Yes	17	4	30.42	13.15	4.40	31.26	
0.5	No	48	8	61.83	12.94	6.10	24.41	
0.5	Yes	9	1	12.54	7.97	0.72	37.18	

		95% Confidence Interval						
		Subjects at risk, n	Subjects with incident ARIA- H<10mm, n	Person- Years	Rate per 100 person-years	Lower Limit	Upper Limit	
1	No	43	4	65.86	6.07	2.03	14.44	
1	Yes	19	2	24.91	8.03	1.60	25.73	
2	No	29	5	38.83	12.88	4.88	28.22	
2	Yes	11	2	14.10	14.19	2.83	45.48	
	ApoE ε4 allele frequency							
Dose mg/kg	0	29	0	34.04	0.00		7.24	
	1	52	1	61.84	1.62	0.15	7.54	
	2	19	2	21.83	9.16	1.83	29.37	
0.15	0	16	1	26.77	3.74	0.34	17.42	
0.15	1	19	0	39.98	0.00		6.16	
0.15	2	7	4	8.06	49.61	16.59	117.95	
0.5	0	22	2	33.91	5.90	1.18	18.90	
0.5	1	29	4	33.94	11.79	3.94	28.02	
0.5	2	6	3	6.53	45.96	12.72	122.62	
1	0	15	0	30.61	0.00		8.05	
1	1	36	5	46.95	10.65	4.04	23.34	
1	2	11	1	13.21	7.57	0.69	35.30	
2	0	19	0	30.29	0.00		8.13	
2	1	13	4	13.44	29.77	9.95	70.77	
2	2	8	3	9.20	32.62	9.03	87.03	
Arm	ApoE ε4 allele frequency							

		95% Confidence Interval						
		Subjects at risk, n	Subjects with incident ARIA- H<10mm, n	Person- Years	Rate per 100 person-years	Lower Limit	Upper Limit	
Placebo	0	29	0	34.04	0.00		7.24	
Placebo	1	52	1	61.84	1.62	0.15	7.54	
Placebo	2	19	2	21.83	9.16	1.83	29.37	
Arm	ApoE ε4 allele frequency							
Active	0	72	3	121.59	2.47	0.68	6.58	
Active	1	97	13	134.31	9.68	5.42	16.08	
Active	2	32	11	36.99	29.73	15.78	51.47	